Some restrictions on the prescribing and use of rosiglitazone-containing diabetes drugs, including Avandia, Avandamet and Avandaryl, were lifted Monday by the FDA based on data showing that they didn't raise the chances of heart attacks. "Although some scientific uncertainty about the cardiovascular safety of rosiglitazone medicines still remains, in light of the new re-evaluation of the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial, our concern is substantially reduced," the agency said. The move means patients will not be required to join a special registry to access the drugs, which will now be sold at most pharmacies.

Related Summaries